Cancer News and Research

Latest Cancer News and Research

NIAID awards DOR BioPharma a $9M grant to develop thermostable and rapidly acting vaccines

DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biotechnology company, announced today that it has been awarded an approximate $9.4 Million grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH).

21 Sep 2009

Results of Phase 1 study of Oral AEZS-112 announced by Aeterna Zentaris

Æterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS) ("the Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced the completion of a Phase 1 study of its orally-active tubulin and topoisomerase II inhibitor compound, AEZS-112, in patients with advanced solid tumors or lymphoma, which may potentially provide a new therapeutic approach for the treatment of cancer.

21 Sep 2009

First Analyses of TYRX's AIGISRx Anti-Bacterial Envelope Retrospective Registry

TYRX, Inc., a leader in the commercialization of implantable medical-pharmaceutical devices, will present the first analyses of results from its AIGISRx Anti-Bacterial Envelope Retrospective Registry during the Transcatheter Cardiovascular Therapeutics (TCT 2009) meeting in San Francisco, CA.

21 Sep 2009

AstraZeneca and Nektar Therapeutics enter worldwide license agreement for two drug development programmes

AstraZeneca and Nektar Therapeutics announced today that they have entered into an exclusive worldwide license agreement for two drug development programmes: NKTR-118, a late stage investigational product being evaluated for the treatment of opioid-induced constipation, and the NKTR-119 programme, an early stage programme that is intended to deliver products for the treatment of pain without constipation side effects.

21 Sep 2009

NIAID awards Antigen Discovery a Phase II STTR grant for Chlamydia vaccine development

Antigen Discovery, Inc. ("ADi", formerly ImmPORT Therapeutics, Inc.), a leading biotech company in high throughput antigen and biomarker discovery, announced today that the Company was awarded a Phase II STTR from the National Institute of Allergy and Infectious Diseases (NIAID) under the American Recovery and Reinvestment Act (ARRA) of 2009.

21 Sep 2009

Ipsen's Azzalure muscle relaxant receives Spanish AEMPS marketing approval

Galderma, the leading pharmaceutical company in dermatology, and Ipsen (Euronext: IPN), an international innovation-driven specialty pharmaceutical group, today announced that Azzalure® (botulinum toxin type A manufactured by Ipsen), a local muscle relaxant specifically developed for aesthetic use, has received a marketing authorization in Spain from the Spanish Medicines and Healthcare products Agency (AEMPS) for the temporary improvement in the appearance of moderate to severe glabellar lines seen at the frown (vertical lines between the eyebrows), in adult men and women aged 65 years and under, when the severity of these lines has an important psychological impact on the patient.

21 Sep 2009

UltraPulse SurgiTouch CO2 laser for the treatment of airway stenosis

Lumenis Ltd., the world's largest medical laser company, announced today that it supplied an UltraPulse SurgiTouch CO2 laser with Digital AcuBlade microsurgery system to the Landspitalinn University Hospital in Reykjavik, Iceland. Lumenis' state of the art laser system, was used by Dr. Paul Castellanos to perform Trans-oral Laser Microsurgery (TLM) for the treatment of airway stenosis with obstructing neurofibromatosis of the laryngopharynx on a 9-year-old girl and four other patients.

From Lumenis Inc. 21 Sep 2009

NASDAQ issues noncompliance letter to Sunesis Pharmaceuticals

Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) reported today that it received a letter, dated September 16, 2009, from the Listing Qualifications Staff (the "Staff") of The NASDAQ Stock Market notifying Sunesis that it does not comply with the minimum $1.00 per share requirement for continued listing on The NASDAQ Capital Market set forth in NASDAQ Listing Rule 5550(a)(2).

21 Sep 2009

Amgen announces results of Phase 3 trial in the treatment of bone metastases

Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3 trial evaluating denosumab administered subcutaneously versus Zometa(R) (zoledronic acid) administered as an intravenous infusion in the treatment of bone metastases in 1,776 advanced cancer patients with solid tumors (not including breast and prostate cancer) or multiple myeloma. These results were presented today at the 2009 ECCO 15 - ESMO 34 European Multidisciplinary Congress in Berlin, Germany (Abstract Number: 20LBA).

21 Sep 2009

Clothes for women who undergo a mastectomy

One in eight U.S. women will be diagnosed with breast cancer during their lifetime, and currently slightly more than half, 56 percent, undergo mastectomy. Few fashion options exist for those who don’t seek reconstructive surgery or postpone it until after their treatment and recovery — a condition the clothier Wear Ease (www.WearEase.com) seeks to remedy.

21 Sep 2009

Research counters criticisms of Canadian health care system

Bloomberg reports that allegations that the Canadian health care system offers inferior treatment, rationing and long lines are wrong, according to wide-ranging and long-standing research.

21 Sep 2009

Today's selection of opinions and editorials

There's enough wrong with the Baucus proposal as it stands to make it unworkable and unacceptable. But that said, Senator Baucus's mark is better than many of us expected. If it serves as a basis for negotiation, and the result of those negotiations is a plan that's stronger, not weaker, reformers are going to have to make some hard choices about the degree of disappointment they're willing to live with (Paul Krugman, 9/17).

21 Sep 2009

Obama: Vitriol on health proposal is 'proxy' for other issues

To advocate for his health care proposal, President Barack Obama taped interviews with five Sunday talk shows (CBS, NBC, ABC, CNN, Univision) and each was allowed to use one excerpt before the programs are broadcast.

21 Sep 2009

GI cancer detection simpler and cost-effective with new blood tests

Berlin, Germany: Promising results from two new blood tests that can aid in the early identification of patients with gastrointestinal (GI) cancers will be presented at Europe's largest cancer congress, ECCO 15 - ESMO 34 [1], in Berlin today (Monday September 21). The tests will make GI cancer detection simpler, cost-effective, and more acceptable to patients than current methods, the researchers say.

21 Sep 2009

ICTs play a major role in the health care sector

Today the GridTalk project launches its 8th GridBriefing at the Enabling Grids for E-sciencE (EGEE) conference in Barcelona. The report covers how information and communication technologies (ICTs), particularly computing grids, are used in the health and biomedical sectors of European research. EGEE has supported this research community since the project's birth and it is the second largest user group after physics research.

21 Sep 2009

Sorrento Therapeutics merge with subsidiary of Quikbyte Software

Sorrento Therapeutics, Inc. ("STI"), a privately-held and development-stage biopharmaceutical company with a proprietary technology platform for the discovery and development of human therapeutic antibodies for the treatment of a variety of disease conditions, has merged with a wholly-owned subsidiary of QuikByte Software, Inc. (OTC Bulletin Board: QBSW), a publicly-traded company with no active operations.

21 Sep 2009

Bioniche Life Sciences' revenue increases by 21% for the fiscal year 2009

Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its 2009 fiscal year ended June 30, 2009.

21 Sep 2009

Study reveals that KCNE2 and KCNQ1 mutations can results in thyroid dysfunction

Genes previously known to be essential to the coordinated, rhythmic electrical activity of cardiac muscle -- a healthy heartbeat -- have now also been found to play a key role in thyroid hormone (TH) biosynthesis, according to Weill Cornell Medical College researchers.

21 Sep 2009

Four single-letter variations in SNPs increse prostate cancer risk

deCODE genetics (Nasdaq: DCGN) today announced that a team of its scientists and academic colleagues from Finland, Spain, the Netherlands and the United States have today published the discovery of four novel single-letter variations in the sequence of the human genome (SNPs) conferring increased risk of prostate cancer.

21 Sep 2009

HIV mutates itself to escape antibodies

A study of how HIV mutates in response to immune system pressure by Emory Vaccine Center researchers shows that the virus can take several escape routes, not one preferred route.

21 Sep 2009